Lexeo Therapeutics (LXEO) versus Its Peers Head-To-Head Survey

Lexeo Therapeutics (NASDAQ:LXEO) is one of 288 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Lexeo Therapeutics to related businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, earnings and institutional ownership.

Insider & Institutional Ownership

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Lexeo Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-155.79%	-51.08%
Lexeo Therapeutics Competitors	-4,884.08%	-211.48%	-46.79%

Valuation & Earnings

This table compares Lexeo Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lexeo Therapeutics	$650,000.00	-$66.39 million	-0.78
Lexeo Therapeutics Competitors	$551.22 million	-$36.07 million	-21.36

Lexeo Therapeutics’ rivals have higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Lexeo Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	0	0	8	1	3.11
Lexeo Therapeutics Competitors	1494	4637	12169	213	2.60

Lexeo Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 26.58%. As a group, “Biological products, except diagnostic” companies have a potential upside of 67.57%. Given Lexeo Therapeutics’ rivals higher probable upside, analysts clearly believe Lexeo Therapeutics has less favorable growth aspects than its rivals.

Summary

Lexeo Therapeutics beats its rivals on 7 of the 12 factors compared.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.